Innovative research and new scientific approaches are key in the treatment of blood cancer.
DKMS is heavily involved in medical science, through our:
We are constantly on a mission to provide more and more people with blood cancer and blood disorders a second chance at life. With this multifaceted approach, we are fighting blood cancer from every possible angle.
When it comes to blood cancer, there are still many unanswered questions. We are investing in and conducting our own research in order to make blood stem cell transplants a lasting success for patients.
Supporting and promoting young researchers is an important part of our work.
The John Hansen Research Grant, (known from 2015 to 2019 as the Mechtild Harf Research Grant), is awarded annually to up to four talented young scientific researchers.
In 2001, the DKMS Foundation for Giving Life (DKMS Stiftung Leben Spenden) introduced the Mechtild Harf Science Award.
Presented each year at the Congress of the European Group for Blood and Marrow Transplantation (EBMT), this prestigious award recognises outstanding research achievements in the field of blood cancer treatment.
The DKMS Clinical Trials Unit (CTU) drives scientific progress in the fight against blood cancer, launching innovative, lifesaving research projects and supporting existing ones.
Our research focuses on allogeneic blood stem cell transplantation, where the cells come from an unrelated donor. This means much of our work is in an area that is of little interest to the pharmaceutical industry, and therefore under-resourced.
The more efficiently we work, the faster patients can be treated.
DKMS is constantly striving to develop and improve the quality and quantity of the DKMS database and the donor data it holds. The database has been significantly improved by the development of our own search algorithm.
The DKMS Life Science Lab, the global leader in HLA typing, analyses cheek swabs or blood samples from potential stem cell donors around the world.
In line with regulatory expectations, the DKMS Life Science Lab is accredited by ASHI and EFI. The Lab is the world's most innovative and efficient HLA tissue typing laboratory of its kind. Our experts carry out typing according to the latest scientific standards, continuously expanding typing profiles. The state-of-the-art workflow enables the analysis of over one million samples per year.
The DKMS Stem Cell Bank is an important resource when it comes to helping patients worldwide even faster.
Often the amount of blood stem cells taken from a donor exceeds the needs of the patient who requires them for the transplantation. With the donor's consent, these surplus cells are frozen, or cryopreserved, rather than disposed of.
This means the stem cells are available to blood cancer patients worldwide for a possible further life-saving transplantation. This way our donors can potentially save two lives with one donation. We will inform our donors who are eligible for a stored donation in the DKMS Stem Cell Bank in advance and ask for an additional declaration of consent.
DKMS was founded in 1991 as a donor centre and later established its donor registry in 2015. As an official registry, we have been listing DKMS-BMST donors from India since 2015 and DKMS donors from Chile since 2018. Listing means that we are storing the information of our donors’ tissue characteristics in pseudonymised form and making them available for worldwide searches for the best possible match between donor and patient.
The DKMS Registry has operated as an independent subsidiary of DKMS since 2020.